AKR1C2 Antibody (T101)

Product Discontinued

AKR1C2 Antibody (T101) Summary

• Immunogen: Hybridoma produced by the fusion of splenocytes from mice immunized with recombinant type 2 dihydrodiol dehydrogenase from human lung cancer and mouse myeloma cells.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: AKR1C2
• Purity: Ascites

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:10 - 1:500
  • Immunohistochemistry 1:10-1:500
• Application Notes: .

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Purity: Ascites

Alternate Names for AKR1C2 Antibody (T101)

• aldo-keto reductase family 1 member C2
• aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acidbinding protein; 3-alpha hydroxysteroid dehydrogenase, type III)
• BABP
• Chlordecone reductase homolog HAKRD
• DD
• DD-2
• DD2DD/BABP
• DDH2FLJ53800
• Dihydrodiol dehydrogenase 2
• Dihydrodiol dehydrogenase/bile acid-binding protein
• EC 1.1.1,3-alpha-HSD3
• EC 1.1.1.213
• EC 1.3.1.20
• HAKRDAKR1C-pseudo
• HBAB
• MCDR2
• pseudo-chlordecone reductase
• Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase
• type II dihydrodiol dehydrogenase
• Type III 3-alpha-hydroxysteroid dehydrogenase

Background

DDH is a member of aldo-keto reductase superfamily1,2, which catalyzes reduction of aldehyde or ketone to a corresponding alcohol by using NADH or NADPH as a cofactor. In liver, the enzyme is abundantly located in the cytoplasm as a monomeric 34-36 kDa protein3,4. Interestingly, by differential display Shen et al.5 has shown that overexpression of DDH could be identified in ethacrynic acid-induced drug-resistant human colon cancer cells. Detection of DDH overexpression in drug-resistant human stomach cancer cells, which were selected by the gradual adaptation to daunorubicin, further suggested that DDH might be associated with the drug-resistance in cancer cells6. In a recent study, DDH expression was further shown to have prognostic significance in patients with NSCLC. By using an immunohistochemical method to determine DDH expression in surgical specimens, DDH expression was identified in patients with leukemia, lung cancer, esophageal cancer, transitional cancer and breast cancer. Furthermore, overexpression of DDH was confirmed by immunoblotting and in situ hybridization. Correlation between clinicopathological parameters and DDH expression as well as the prognostic significance of DDH expression in patients with advanced cancer was indicated.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: AKR1C2